Express Pharma

SEPTEMBER 24, 2023

The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). This ascent is propelled by favorable regulatory developments, including pioneering clinical trial guidelines from the FDA. billion in sales in 2029.

Drug Development 52

Drug Development Compounding 52

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

Express Pharma

DECEMBER 28, 2023

One of the recent examples is Bayer’s announcement of a cooperation with Shanghai Pharmaceuticals China in November 2023 to set up its first Chinese lab for CGT and cancer drug development. According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029.

Drug Development 105

Drug Development 105

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.

Immunization 143

Immunization Immunity Drug Development 143

European Pharmaceutical Review

OCTOBER 26, 2023

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.

Chemotherapy 105

Chemotherapy Drug Development 105

FDA Law Blog: Biosimilars

DECEMBER 23, 2024

Earlier in the week, it was reported that there was a bipartisan agreement on a bill that would have funded the government and extended the first sunset date for the rare pediatric disease priority review voucher program for nearly 5 years, until September 30, 2029.

Drug Development 59

Drug Development 59

Express Pharma

NOVEMBER 13, 2023

However, tarlatamab, a bispecific T-cell engager (BiTE) developed by Amgen, recently demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. The Phase II DeLLphi-301 trial focused on patients with SCLC undergoing two prior treatment regimens.

Drug Development 40

Drug Development 40